[Evolving strategies for relapsed multiple myeloma: Toward personalized treatment in 2026].

Authors

Pierre-Edouard Debureaux, Titouan Cazaubiel, Thomas Chalopin, Alexis Talbot

Published in

Bulletin du cancer. Sep 28, 2026. Epub Sep 28, 2026.

Abstract

Multiple myeloma (MM) is a malignant plasma cell disorder whose prognosis has significantly improved with the introduction of proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and more recently BCMA-targeted immunotherapies. In 2026, MM is considered a chronic disease requiring individualized sequential treatment strategies. Frontline management is guided by patient fitness, enabling treatment intensity adaptation. At relapse, therapeutic decisions depend on prior response duration, refractoriness, previous drug exposure, and comorbidities. In early relapse, anti-CD38-based combinations, as well as carfilzomib- or pomalidomide-based regimens, remain standards of care. In later lines, BCMA-targeted immunotherapies, including bispecific antibodies and CAR-T cell therapies, have reshaped outcomes. However, these approaches raise challenges related to infectious toxicity and treatment logistics. Optimizing treatment sequencing is therefore critical, integrating disease biology, patient characteristics, and prior therapies.

PMID:
42805821
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.